CD24 and endometrial cancer: In addition, experiments are under way to explore the utility of [89Zr]Zr-DFO-trastuzumab and [89Zr]Zr-DFO-ATG-031 as companion theranostics in endometrial cancer alongside HER2-targeted antibody–drug conjugates and CD24-targeted immunotherapeutics.